GlassScriptPhysician profile
Kerri L Stone
NPI 1053077198
$1,015.62
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $965 · 2024: $50.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $169.95 | 2023 | Jakafi, Pemazyre, Monjuvi |
| Celgene Corporation | $72.14 | 2023 | Reblozyl |
| Seagen INC. | $67.92 | 2023 | Adcetris |
| Merck Sharp & Dohme LLC | $66.52 | 2023 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $66.28 | 2023 | Zejula, Shingrix |
| Pfizer INC. | $54.88 | 2023 | |
| Eisai INC. | $52.78 | 2023 | |
| Abbvie INC. | $50.42 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.60 | 2023 | |
| Janssen Biotech, INC. | $38.91 | 2023 | Rybrevant, Imbruvica |
| Lilly USA, LLC | $36.36 | 2023 | Jaypirca, Retevmo, Verzenio |
| Genzyme Corporation | $32.53 | 2023 | |
| Emd Serono, INC. | $28.64 | 2023 | Bavencio |
| Apellis Pharmaceuticals, INC. | $27.65 | 2023 | Empaveli |
| Regeneron Healthcare Solutions, INC. | $23.40 | 2023 | Libtayo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.57 | 2023 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $21.19 | 2023 | Imbruvica, Epkinly |
| Novartis Pharmaceuticals Corporation | $20.71 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.68 | 2023 | Imfinzi |
| Daiichi Sankyo INC. | $18.25 | 2023 | |
| Tersera Therapeutics LLC | $17.25 | 2023 | Zoladex |
| Mirati Therapeutics, INC. | $15.81 | 2023 | Krazati |
| Alnylam Pharmaceuticals INC. | $15.11 | 2023 | Givlaari |
| Array Biopharma INC | $14.72 | 2023 | Xalkori, Lorbrena, Braftovi |
| Amgen INC. | $14.35 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.